The AFR has published an interesting piece about NYR-330 - see
http://www.nyrada.com/site/PDF/1109...nBiotechLowercholesteroltreatmentbreakthrough
Graham Kelly has shown his confidence in Nyrada by signing up to an incentive-laden package with Nyrada that includes:
110,000 warrants granted on achieving market cap of A$400m;
110,000 warrants granted on achieving a successful M&A, trade sale or licensing deal worth a minimum US$500m in respect of any one of the Company's clinical programs.
Noxopharm owns 67% of Nyrada.
NYX-330, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $555 | 5.296K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 95000 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 151971 | 2 |
View Market Depth
| Last trade - 15.18pm 22/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
